團隊
Home >> People >> Partner >> Jill Niu
牛豫燕 Jill Niu

Jill Niu

Partner

聯絡方式

Jill is one of the partners heading Lee & Li's Healthcare and Life Science Practice Group. She has been an attorney in Taiwan for more than 30 years and she has been working at Lee & Li for more than 20 years. Since she joined Lee & Li in 2001, she has been advising for many of the firm's healthcare/life science industry clients on various types of matters including product registration and regulatory compliance, clinical trials, activities of sales, marketing and promotion of healthcare products, interactions with HCPs/patient groups and privacy/data protection issues. Jill also has extensive experience in assisting local chain medical centres in establishing SOP for risk management and in negotiations and mediations on malpractice claims and other claims in connection with medical services and counselling local healthcare associations, including the ROC International Research-Based Pharmaceutical Manufacturers Association and Taiwan Advanced Medical Technology Association, in respect of the code of marketing practices. Jill was a member of the Research Ethic Committee of the National Health Research Institutes (2012-2020). Jill acted as the legal counsel to Taipei Medical Instrument Commercial Association (2016-2019) and she is also currently serving as the legal counsel to Taiwan Federation of Medical Devices Commercial Association (2024-2026).

Jill is also one of the partners heading Lee & Li's Labor Law Practice Group. Her expertise in employment law covers all aspects thereof, including advising on recruitment and employment termination issues, conducting employee disciplinary investigations, handling employment related disputes including mediation and litigation regarding post-termination issues such as breach of non-compete and non-solicitation obligations. She has also been continuously advising on executive benefits and compensation issues and employee transfer/mass redundancy issues/matters as a result of business transfer/transformation. Her recent experience includes successfully defending a multi-national healthcare corporate client in a lawsuit regarding wrongful termination by a former country manager, assisting several MNC pharmaceutical companies in conducting disciplinary investigations involving breach of marketing practices, bribery and corruption issues and in negotiating mutual termination agreements for executive personnel and assisting a multi-national chemical client in a settlement with employees' claims for occupational hazard compensation.

In addition to the healthcare industry/products, Jill advises on product regulatory and product liability matters on tobacco, beverage/alcohol, food (infant formula, health food, and supplements), and cosmetics. Her expertise covers market access/pre-market approvals, product recalls, and other product regulation issues in Taiwan.

Jill's specialty in healthcare law and employment law has been recognized and named as a "Thomson Reuters Stand-out Lawyer - independently rated lawyers".

學歷

LL.B., National Taiwan University Law School (1991)

專業領域

Healthcare & Life Sciences; Employment; Data Privacy; Product Liability; Litigation & Arbitration

經歷

Associate, JonesDay, Taipei Branch
Associate, Ding & Ding, Law Offices
Associate, Kao & Associates Law Firm
Member of Research Ethic Committee, the National Health Research Institutes
Legal Counsel, Taipei Medical Instrument Commercial Association
Legal Counsel, Taiwan Federation of Medical Devices Commercial Association
Courses Planning Counselor, Graduate Institute of Health and Biotechnology Law, TMU
Lecturer, Graduate Institute of Health and Biotechnology Law, TMU; Graduate Institute of Biomedical Science, CMU; Clinical Research Center, CSH; KMUH; NTUH-Yunlin Branch; NCKUH; NHRI, Foundation of Medical Professionals Alliance in Taiwan;

資格

R.O.C. licensed patent agent (1998)
Admitted to Taiwan Bar Association (1992)

語言

Mandarin, English, Taiwanese Hokkien

2023 Court rules in favour of pharmaceutical companies that market category two new drugs
ILO IP Newsletter (20230424)
2023 Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEXOLOGY
2023 Lexology GTDT Market Intelligence - ESG Engagement & Litigation 2023 - Taiwan
GTDT Market Intelligence - ESG Engagement & Litigation 2023
2023 ESG Engagement & Litigation | Taiwan
GTDT Market Intelligence ESG Engagement & Litigation 2023
2023 Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEE & LI Bulletin - January 2023
2022 Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEXOLOGY
2022 Constitutional Court Found National Health Insurance Database Lacking Proper Privacy Protection and Ordered Relevant Laws be Amended or New Laws be Promulgated within Three Years
LEXOLOGY
2022 Constitutional Court Found National Health Insurance Database Lacking Proper Privacy Protection and Ordered Relevant Laws be Amended or New Laws be Promulgated within Three Years
LEE & LI Bulletin -October 2022
2022 Medical Devices & Consumer Health Products 2022 – Taiwan
Chambers Global Practice Guides: Medical Devices & Consumer Health Products 2022

More


2023 Regulatory Insights for Regenerative Medicine in Taiwan and Business Shifts | Speaker
Lee and Li, Attorneys-at-Law, ERM Taiwan
回上一頁